<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Arrowhead Pharmaceuticals, Inc.

    Arrowhead Pharmaceuticals, Inc.

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by si...

    Arrowhead Pharmaceuticals develops medicines th...

    Filing Type:    PU
    Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...

    Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...

    Filing Type:    PU
    ADMA Biologics Inc

    ADMA Biologics Inc

    We are a vertically integrated commercial biopharmaceutical company that develops,...

    We are a vertically integrated commercial bioph...

    Filing Type:    PU
    Biolase, Inc.

    Biolase, Inc.

    BIOLASE, Inc. is a medical device company and global market leader in the manufact...

    BIOLASE, Inc. is a medical device company and g...

    Filing Type:    PU
    EDAP TMS S.A.

    EDAP TMS S.A.

    Global leader in therapeutic ultrasound and present in the market for more than 35...

    Global leader in therapeutic ultrasound and pre...

    Filing Type:    PU
    Guardion Health Sciences, Inc.

    Guardion Health Sciences, Inc.

    Guardion Health Sciences is at the forefront of early detection, intervention and ...

    Guardion Health Sciences is at the forefront of...

    Filing Type:    PU
    Cue Biopharma, Inc.

    Cue Biopharma, Inc.

    Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...

    Cue Biopharma is an innovative clinical stage i...

    Filing Type:    PU
    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...

    Atara Biotherapeutics is a leading off-the-shel...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    Bio-Path Holdings, Inc.

    Bio-Path Holdings, Inc.

    Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...

    Bio-Path is a biotechnology company developing ...

    Filing Type:    PU
    Karyopharm Therapeutics Inc.

    Karyopharm Therapeutics Inc.

    Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...

    Karyopharm Therapeutics is an innovation-driven...

    Filing Type:    PU
    bluebird bio, Inc.

    bluebird bio, Inc.

    bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...

    bluebird bio is pioneering gene therapy with pu...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.